HEALTHBLOOMBERG
Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Avalyn, a drugmaker backed by Novo, raised $300 million in an upsized IPO. Its drug AP01 has completed a clinical trial for idiopathic pulmonary fibrosis.
Avalyn, a drugmaker backed by Novo, raised $300 million in an upsized IPO. Its drug AP01 has completed a clinical trial for idiopathic pulmonary fibrosis.